Table of contents

CEO message

Genomics
for Good

Introduction

2023 CSR Report

Illumina Corporate Social Responsibility
Executive Summary Report 2023

CSR at Illumina

AccessPeopleSustainability

Responsibility
1Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
22023 CSR Report

At Illumina, we are
driven by the powerof genomics topositively impact theworld and shape amore sustainable andequitable future for all.

TA B L E O F C O N T E N T S
3 A message from our CEO
4 Introduction

17 Accelerate access to genomics
18 Strategic approach and impact

5 2023 CSR highlights

19 Nurture our people and communities

6 Celebrating 25 years of Illumina

20 Strategic approach and impact

7 Recognition

21 Our people

8 About Illumina
9 Business overview
10 CSR at Illumina
11 CSR governance
13 CSR strategy
14 Materiality
15 Engaging our stakeholders
16 Progress on our 2030 targets

22 Integrate sustainability
23 Strategic approach and impact
24 Driving climate action across our value chain
25 Operate responsibly
26 Strategic approach and impact
27 About this report

Read the full CSR
report here.

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
32023 CSR Report

Message from our CEO
Since joining Illumina, I’ve witnessed the passion ourcustomers, employees, and partners share around
improving human health by unlocking the power ofthe genome. As an industry leader, Illumina is uniquely
positioned to advance the adoption of genomics
across the life sciences ecosystem with our innovative
products, services, and solutions.
Despite challenging market conditions, we’vemaintained our steadfast commitment to serving
customers and supporting our environmental, social,and governance priorities. Aligned with our businessstrategy and core Illumina values, we continue
taking bold, meaningful steps to accelerate accessto genomics, empower our communities, integrate
environmental sustainability, nurture our people, andoperate responsibly.

Make our customers the heroes in their labs
Our customers' ambition to solve humanity's biggest
challenges inspires us to push the boundaries of what
is possible and create the genomics tools that canturn big ideas into life-changing discoveries. Our goal
is to make them the heroes in their labs, armed with acomprehensive portfolio of core sequencing innovation,
sample-to-answer solutions, and lab services.

Accelerate access to genomics
Bringing the benefits of genomics to more people
requires driving down the cost of sequencing,
expanding into new markets, and increasing thediversity of genomic data. In 2023, we trained morethan 27,000 health care professionals and increased thenumber of patients covered for genomic testing from
1.2 billion to 1.3 billion. In Canada, we helped fund a
new project aimed at bridging the diagnosis gap for theregion’s Indigenous children, just one of many initiatives
we support to increase diversity in human genetics.

We also launched several new products, including
the NovaSeq™ X Systems, powered by XLEAP-SBS™
chemistry; our TruSight™ Oncology 500 ctDNA v2
research assay, enabling comprehensive genomic
profiling from liquid biopsy samples; and the 25B flow
cell, which can generate tens of thousands of wholegenomes per year at the lowest cost per sample ofany Illumina platform.

Our customers' ambition to solve
humanity's biggest challenges
inspires us to push the boundaries
of what is possible and create thegenomics tools that can turn big
ideas into life-changing discoveries.”

Jacob Thaysen
Chief Executive Officer

Jacob Thaysen
Chief Executive Officer

Nurture our people and help them thrive
I’m incredibly proud of our global team. We share apassion for improving the world around us throughgenomics, and believe in the power of an inclusive,
collaborative, and caring workplace. In 2023, we
maintained a zero net pay gap for the fifth consecutive year; and reached 45% female workforce
representation, with a 5% increase in female leadershiproles over the last three years. Nearly 60% of ourglobal employees participated in charitable giving
and volunteering during the year.

Integrate environmental stewardship into
our business and innovations
We know improving human health is tied to creatinga healthier planet. Making bold environmental
commitments, and helping customers achieve theirsustainability goals, is part of our role as an industry
leader. Launched in 2023, our NovaSeq X instruments
improve the sustainability of reagents with 90% lesspackaging, 50% less plastic, and a 61% reduction inclimate change impact. Additionally, in 2023 weachieved 100% renewable electricity* for a second
consecutive year.

Operate responsibly in all that we doEvery minute, approximately 7.5 human genomes aresequenced on an Illumina platform. That impact comeswith great responsibility. We're committed to operatingwith integrity and adhering to high ethics, privacy,
and security standards. In 2023, 100% of Illumina corefacilities participated in third-party audit programs. In
addition, we expanded our ISO data privacy certification
to include additional products and completed the

EU-US and Swiss-US Data Privacy Framework selfcertification and ISO 27701 certification.

Our next 25 years of innovation
Founded in 1998, Illumina has proven time and timeagain how unlocking the power of the genome can
exponentially improve the human condition. The futureis bright for Illumina and our industry, as we consider
the role genomics can play in improving the health ofthe planet and its people. Thank you to our customers,
partners, and employees around the world for helping
bring our mission to life. I look forward to continuing ourjourney as we build a stronger, healthier world together.
Jacob Thaysen
Chief Executive Officer

Table of contents

CEO message

Introduction

2023 CSR Report

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
4

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
52023 CSR Report

2023 CSR highlights
AC C E L E R AT E AC C E S S
TO G E N O M I C S

N U R T U R E O U R P EO P L E
AND COMMUNITIESI N T EG R AT E
S U S TA I N A B I L I T Y

O P E R AT E
R E S P O N S I B LY

1.3 billion

Zero

100%

100%

Comprehensive
genomic profiling

52%

90%

11%

352

5%

100%

Completed> 27,000

58%

8%

91%

lives covered

enabled for liquid biopsy
samples‡ launched

NovaSeq X Series instruments
enabling whole-genome
sequencing (WGS) at $200 USD
genome* shippedTM

health care professional
learners reached

net pay gap maintainedfor fifth consecutive year

minority representation in
the US workforce

increase in female executive
leadership representation in
the last three years

employee participation in giving
and volunteer programsof global electricity consumption
came from renewable sources

less packaging weight and waste
in NovaSeqTM X Series reagentsof our strategic supplierscommitted to minimize theirenvironmental footprint

decrease in water consumption(YoY) at core sites†*$200 USD genome on NovaSeq X Series is delivered at list price on 25B flow cell. Data on file.
†Core sites: San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison, UK Illumina Centre, the Netherlands, and Singapore Woodlands.

‡

With our new TruSight™ Oncology 500 ctDNA v2 research assay.

of Illumina core facilities participatedin third-party audit programs

diverse supplier spend

The EU-US and Swiss-US
Data Privacy Framework (DPF)
Self-Certification and ISO 27701
Certification

independent Board of
Directors (all independent
with exception of CEO)

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
62023 CSR Report

Celebrating
25 years of
Illumina

2019

Researchers used the MiniSeqTM
System to sequence a sample of
COVID-19 in Wuhan and enabled
partners to develop the vaccines
without a live virus.

2017

Since its inception in 2017, our market
access team has been working withconsortia, governments, payers, andothers to increase insurance coveragefor genetic testing. 1.3 billion lives are
now covered. Learn more

2023

2008

Illumina completed the first-eversequencing of an African humangenome. From the very beginning,
we have prioritized increasing
genomic data diversity. Learn more

2001

2020

2018

We launched our first
product.

[image of first
product – array
technology]

2010

On June 9, we received
the first FDA Emergency
Use Authorization fora sequencing-based
COVID-19 diagnostic test.

We began shipping the NovaSeq
X Series, our most powerful andsustainable high-throughput NGS
systems, resulting in the ~$200
genome* and a 61% reduction inclimate change impact†

We introduced a pan-cancer assay
designed to identify known andemerging tumor biomarkers, helping
to accelerate the field of precisiononcology with comprehensive
genomic profiling.

We brought the cost of sequencing
a human genome from $150,000 to$10,000 with the Illumina HiSeqTM 2000.
Learn more about how we’re making
genomics more affordable.

2007
1998

Illumina was founded.

We launched the Genome AnalyzerTM,
introducing the world to Illumina
sequencing by synthesis (SBS)
chemistry, advancing sequencing
chemistry to be faster, more accurate,
and more stable.

*$200 USD genome on NovaSeq X Series is delivered at list price on 25B flow
cell. Data on file.
†

Compared with NovaSeq 6000 reagents.

Table of contents

CEO message

Introduction

CSR at Illumina

Recognition 2023
Recognition for Excellence in Singapore(CARES)•Military Times Best for Vets
•MSCI CSR (AA)•Newsweek America's Greatest
Workplaces for Diversity••Community Chest Singapore Charity Silver•Disability Equality Index, Best Places to Work•Newsweek America’s Greenest•Dow Jones Sustainability Indices•EcoVadis Silver Sustainability Rating•Fast Company’s Innovation by Design•Newsweek Excellence Index•Refinitiv Top 100 Global Diversity

CDP Supporter

for Disability Inclusion

Awards for the NovaSeq X Series (Honoree)•Fast Company’s World Changing Ideas

Awards for the NovaSeq X Series (Honoree)•Forbes America's Best-In-State Employers•Forbes World's Best Employers•Forbes World’s Top Companies for Women•FTSE4Good Index•IBO Gold Award for Design for the NovaSeq
X Series••JLens CSR Awards•Just Capital and CNBC America's
ISS CSR 1 | 1 | 10

Most Just Companies

PeopleSustainability

Responsibility
72023 CSR Report•3BL 100 Best Corporate Citizens•AmCham Corporate and Societal Action:

AccessCompanies•Newsweek America’s Most Responsible
Companies

and Inclusion Index•S&P Global's Sustainability Yearbook
Member•SANDAG iCommute Diamond Awards•Sustainalytics Morning Star | Industry Top
Rated CSR

•The Straits Times Singapore's Best
Employers•TIME World's Best Companies•U.S. News & World Report Best
Companies To Work For•Workplace Safety and Health Council
Silver Award (Singapore)Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
82023 CSR Report

About Illumina

We are a global genomics and human health leader innovating the future of precision health. Unlocking the power of genomics
is exponentially improving the human condition. This is why we are committed to driving continuous innovation and deep
collaboration that will enable positive and impactful people- and planet-healing solutions.
O U R PR O M I S E

OUR MISSIONO U R PU R P OS E

To improve human healthby unlocking the powerof the genome.

Drive the positive progressof genomics to make it
useful for all.

We deliver breakthroughs that
redefine what’s possible in genomics
and accelerate impactful healthadvances globally.

O U R PR I N C I PLES

Accelerating
accessRedefining
possible

Leading purposefuladvances

Broadening impact
with collaborations

Making genomics accessible is critical inrealizing its potential to save and improve
lives. That’s why we are committed to driving
down the cost of sequencing, expanding
access to advanced technology, andincreasing the diversity of genomic data.

The genome has the potential to solve
humanity's biggest challenges. Our
industry-leading technology enables
researchers and clinicians to turnbig dreams into impactful genomic
discoveries that improve lives andchange the course of diseases globally.

Our passion for supporting customers andhelping them achieve their goals guides what
we do. Inspired by deep customer insights, welead the way in delivering purposeful advancesthat address critical needs and support
researchers and clinicians as they make lifechanging breakthroughs and decisions.

Improving health at scale requires visionand collaboration with changemakers
across the ecosystem. Together,
we're finding answers to life's biggest
questions and broadening the positive
impact of genomics around the world.

O U R VA LU ES

Innovation
is in our DNA

We are relentlessin the creation ofgreat products

We collaborate
deeplyWe move fast andembrace change

We are open

The power of genomics
What causes a cancer cell to mutate? How do we identify a novel
virus and create a vaccine? How do we diagnose a rare genetic
disease? How do we safeguard the world’s food supply? What effectdoes climate change have on biodiversity? The answer to these andthousands more of life’s most pressing questions can be found in theworld of genomics.

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
92023 CSR Report

Business overview
C O R E I L LU M I N A AT A G L A N C E

1998

~9300

founding year

employees$1 billion+~9500

in R&D (GAAP)

customers

450,000+

9893

sequencing publications

patents worldwide

C O R E I L LU M I N A R E V E N U E$4.44 billion

6% 5-Core Illumina 2023 revenue

25,000+

YEAR

CAGR

$4.5B
$3.3B

$3.5B

$4.6B

$4.4B

70%

Consumables

$3.2B

16%

instruments installed

Instruments

160+

countries receive our products

2018

2019

2020

2021

2022

2023

14%

Service and OtherM A R K E T S EG M E N T S

Oncology

Reproductive Health

Genetic Disease

Research/Applied Genomics

Infectious Disease

Drug Discovery

Multi-Omics

S EQ U EN C I N G SYSTEM S
LOW-THROUGHPUT

MiSeqTMMiniSeqTM

MID-THROUGHPUT

iSeqTM 100

NextSeqTM 500

NextSeqTM 550

NextSeqTM 1000/2000

HIGH-THROUGHPUT

NovaSeqTM 6000

NovaSeqTM X Series

DIAGNOSTIC

MiSeqTM Dx

NextSeqTM 550Dx

NovaSeqTM 6000Dx

Table of contents

CEO message

Introduction

CSR at Illumina

2023 CSR Report

CSR at Illumina

AccessPeopleSustainability

Responsibility
10

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
112023 CSR Report

CSR governance
CSR is integral to how we do business. Our governance structure
facilitates accountability, transparency, and continuous improvement.
1

1
Board
of Directors

2
Nominating/Corporate
Governance Board Committee

3
CSR Executive Steering Committee

4
Philanthropy Governing Board

5
External Ethics Advisory Board

6
CSR Functional Group

7

The Board of Directors governs the managementof our material CSR issues and receives updates
on current performance and future strategic plansat least annually or more frequently if materialchanges occur.

2 The Nominating/Corporate GovernanceCommittee assists the Board in overseeing
the company’s material CSR issues, except as
specifically delegated to another Board committee(the Compensation Committee oversees DEI and
the Audit Committee oversees cybersecurity).
3 The CSR Executive Steering Committee provides
guidance on CSR strategic plans and practices,
approves major programs, and monitors progress
toward targets. It comprises senior leaders,
including the general counsel, chief of global
operations, chief people officer, chief technology
officer, chief marketing officer, vice president ofinvestor relations, and global head of CSR.
4 Philanthropy Governing Board
The Illumina Corporate Citizenship Steering
Committee has oversight on philanthropic
contributions from Illumina. The Illumina Corporate
Foundation Board governs the philanthropy
associated with the Illumina Corporate Foundation,
a separate entity and private foundation.

5

The External Ethics Advisory Board
provides guidance on a range of strategic
issues, including recommendations
on emerging ethics matters, policies,and regulations that are relevant to the
genomics industry.

6

The CSR Functional Group is responsible
for strategy development, program
implementation, and CSR reporting.

7

Supporting CSR Working Groups:

8

Employee Engagement Groups:•Executive Diversity Council•EHS Steering Committee•Quality Council•Sustainable Product Core Team
•Supplier Diversity Committee•Privacy Steering Committee•Sustainability Green Teams•Illumina Cares Volunteer Ambassadors•Employee Resource Groups (ERGs)

Working Groups

8
Employee Engagement Groups

Select CSR targets are included in annual corporate goals and influence executive compensation
through the management performance scorecard.
Learn more about our Board governance, member tenure, independence, and diversity.

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
122023 CSR Report

CSR integration
into our business
Our CSR strategy is guided by our businessstrategy and the voice of our stakeholders.
It provides a lens to evaluate risks andopportunities to foster and promote long-term
shared value.
Governed by our Board of Directors, our CSR strategy
promotes the sustainable stewardship of our business byfocusing on accelerating access to genomics, nurturing ourpeople and communities, integrating sustainability into our
products and operations, and operating responsibly.
AccessWith our mission to improve human health by unlocking
the power of the genome, we are committed to making our
products more affordable, accessible, and sustainable.
PeopleThe success of our mission relies on engaging extraordinary
talent and helping them thrive. Putting people first and doing
the right thing is core to who we are and what we do.
Sustainability
Genomics has the potential to solve humanity’s biggest
challenges and the planet’s most pressing issues. We
integrate sustainability in our operations, products, and value
chain with recognition that human health and the health of ourenvironment are intertwined.
Responsibility
As genomic pioneers, we hold ourselves to the highest
standards in our actions, ensuring that the technology wecreate and the data we collect are used safely, ethically,
and responsibly. We are committed to transparency andconnected by a dedication to genomics for good.

By embedding our CSR strategy into our business, we are driving
positive stakeholder impact and long-term shareholder value.

ImpactNurture our people
and communities

Integrate
sustainability

Accelerate accessto genomics

Operateresponsibly

CSR vision
Deepen our impact on humanhealth by serving as a champion
for patients, our communities,
our people, and our planet.

PurposeDrive the positive
progress of genomics tomake it useful for all.

MissionImprove humanhealth by unlocking
the power of thehuman genome.

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
132023 CSR Report

CSR strategy
We are deepening our impact on human health by serving as achampion for patients, our communities, our people, and our planet.

Accelerate access to genomics

Nurture our people and communities

Integrate sustainability

Operate responsibly•Be the engine of genomic innovation•Drive down the cost of sequencing•Expand the reach of genomics•Practice diversity, equity, and inclusion•Attract extraordinary talent•Invest in our people•Support employee health, well-being, and safety•Engage our employees and communities•Drive climate action•Operate sustainable facilities•Develop sustainable products•Leverage genomics for sustainability applications•Practice strong corporate governance

UN SDGUN SDGUN SDGand compliance•Act ethically and with integrity•Uphold high standards for data security
and privacy•Foster a responsible supply chain•Advance product quality and safety
UN SDGTable of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
142023 CSR Report

Materiality
We prioritize action on our most material* environmental, social, and governance(ESG) issues, supported by robust governance, transparency, and accountability.
Through managing the risks and opportunities related to each material ESG issue, we
execute on our purpose and deliver the greatest positive impact to our business, ourstakeholders, and the planet.

Reporting frameworks and external benchmarking

Our materiality assessments guide our CSR strategy by understanding whichmaterial issues matter most to our business, our stakeholders, and society. In 2021,
we refreshed our 2018 baseline materiality assessment, which further refinedand validated our priorities and focus areas. The updated materiality assessment
incorporated principles of a double materiality approach by understanding which
topics could have a potential impact on our business and which topics have apotential impact on external stakeholders, society, and the environment.
In this report, we outline our management approach, targets, connection to the United
Nations Sustainable Development Goals (UN SDG), and performance for each ofour material CSR topics. Our reporting efforts align with the leading frameworks andexternal benchmarking tools.

Material CSR topics

Employees

ENVIRONMENTSOCIALG OV E R N A N C E•Climate action•Sustainable facilities•Sustainable products•Access, innovation,•Supply chain management•Data privacy

and affordability•Human capitalmanagement†

and cybersecurity•Corporate governance•Business ethics•Product quality and safety

Customers

Suppliers

Investors

Nonprofits

Distributors

We engagewith a wide
range ofstakeholders

Channelpartners*In this report, we use the terms “material” and “materiality” to refer to topics that reflect the meaningful environmental,social, and governance impact of Illumina. The use of such terms shall not be deemed to constitute an admission as tothe materiality of any information in this report for purposes of applicable securities laws or any other laws of the UnitedStates, nor are we using them as they are used in the context of financial statements and financial reporting.
The human capital management topic includes the following themes: DEI, recruitment, development, engagement,
safety, and wellness.
†

CSR peergroupsCommunity partners

Industry leaders

Health care providers

Governments & regulatory

We routinely gather feedback on
ESG topics from our stakeholders
and work to create an open
dialogue. We are committed tooperating with transparency andopen communication to develop
trusted relationships with all
our stakeholders. Stakeholder
feedback is embedded into our
CSR strategy and programming.

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
152023 CSR Report

Engaging our stakeholders
Stakeholder
groups

How we engage

How we respond

Investors

Investor Day, CSR Virtual Investor Event, quarterly and annual reports, regular meetings, andcommunication via phone, email, and website.

Based on feedback for increased accessibility of data, we created an CSR data hub on our website that promotes
quick access to our CSR targets, policies, and performance.

Customers

Our Customer Experience team regularly surveys customers to understand how we can improve. We
conduct quarterly relationship surveys, leverage machine-learning tools, and provide an open channel
for customer feedback from our field employees. In 2023, we achieved a Customer Net Promoter
Score of 54, and 9 out of 10 customers find it easy to do business with our team.

We received feedback from customers on the sustainability of our products and on decreasing the amount of
packaging we use. With the launch of the NovaSeq X Series, we were able to reduce packaging by 90% and achieve
a 61% reduction in climate impact.* Learn more

We partner with patients, families, and organizations that represent communities to help raiseawareness, build hope, and create change.

Work from scientists at Illumina and our collaborators has shown that patients who get access to whole-genome
sequencing (WGS) are twice as likely to have a change in management and are more likely to get the precision carethey need. As of 2023, over 1.3 billion lives are covered for genomic testing. Learn more

Patients

Through evidence generation, education, and community outreach, Illumina is committed to
advocating for health care coverage and accelerating the adoption of genomics as a diagnostic tool.
We engage and communicate with our employees via regular pulse surveys, virtual and in-personcompany meetings, email, internal events, performance reviews, training, ERGs, recognition, and otherinternal platforms.

We received feedback that leaders wanted development opportunities, which resulted in delivering global leadershipprograms targeted to every leadership level in 2023. Learn more

Suppliers

Our procurement and supply chain management team engages suppliers through tenders, training,surveys, meetings, and questionnaires.

In 2023, we expanded our current practices to protect and promote the right to freedom from forced labor andmodern slavery by engaging with a third party to help us initiate human rights due diligence of our supply chain.
Learn more

Health care providers

We aim to increase genomic literacy by engaging health care professionals through podcasts, online
education, roundtables, conferences, and meetings.

In 2023, through independent medical education partnerships with professional societies and the medical
community, we provided education across all clinical segments, reaching 27,000 learners and measuring a 99%
increase in participant knowledge and a 98% increase in competence reported. Learn more

Community investment grant recipients complete both a mid-grant and final impact survey following
completion of their projects to help guide future opportunities and provide feedback.

In 2023, a STEM nonprofit grantee working to create a mobile lab experience communicated delays in construction
when they filed their mid-year grant surveys. This feedback enabled us to adjust the launch activation of their exhibit
and find alternative volunteer options onsite for our employees while the mobile lab was being completed.
Learn more

Illumina connects with governments and organizations around the world to engage and educate
policymakers and key stakeholders on issues that impact our mission and business.

In 2023, we focused engagement with public-policy stakeholders around advancement of precision medicine;
adoption and reimbursement for genetic testing; adoption and reimbursement for noninvasive prenatal testing;adoption and funding for genomic infectious disease surveillance; and promotion of STEM opportunities.

We seek guidance from our Ethics Advisory Board quarterly on a range of strategic issues.

The Ethics Advisory Board’s work includes providing strategic advice to Illumina about emerging policies andregulations relevant to the genomic industry and the company’s interests, and ethical issues arising from specifictechnology or products.

Employees

Community partners

Government andregulators

Ethics Advisory Board*Based on end market assessment NY, US.

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
162023 CSR Report

Progress on our 2030 targets
Our focus areas

Objectives

Accelerateaccess to
genomics

2 Drive down the cost of sequencing

2030 Targets

1 Be the engine of genomic innovation

Achieved

In Progress

2023 Progress

Achieve 2 billion covered lives by 2026
Reach at least 25,000 medical education learners annually
Reach 5 million STEM learners

3 Expand the reach of genomics

1.3 billion lives covered>27,000 medical education learners reached
1.6 million STEM learners reached from 2019 baseline

SDG Alignment
Targets: 3.d, 17.6, 17.7, 17.16

Nurture ourpeople andcommunities

Increase gender representation in global leadership*
Maintain zero net pay gap
Increase minorities** in executive leadership‡ (US)Increase underrepresented minorities§ in US workforce and leadership*
Reduce recordable injury and illness rate
Donate 100,000+ volunteer hours
Achieve 50% employee participation in giving and volunteering

1 Practice diversity, equity, and inclusion
2 Attract extraordinary talent
3 Invest in our people
4 Support employee health, safety, and well-being
5 Engage our employees and communities

4% increase from 2019 baseline
Maintained for 5th consecutive year
8% increase from 2019 baseline
2% increase in leadership; 1% increase in workforce from 2019 baseline
48% decrease from 2019 baseline
47,130 volunteer hours donated from 2019 baseline
58% employee participation

SDG Alignment
Targets: 10.3, 5.bIntegrate
sustainability

1 Drive climate action
2 Operate sustainable facilities

Deliver net zero emissions (Scope 1,2,3) by 2050
Reduce emissions by 46% (Scope 1,2)
Reduce emissions by 46% (Scope 3)
Achieve 100% renewable electricity
Reach 90% landfill diversion at core sites
Reach 10% reduction in water intensity at core sites
Reduce packaging by 75%

3 Develop sustainable products
4 Leverage genomics for sustainability applications

In progress
48% decrease from 2019 baseline†
16% increase from 2019 baseline; 24% decrease YoY
100% renewable electricity†
56% landfill diversion at core sites
2.6% increase in water intensity at core sites; 8.3% decrease YoY in total water consumption
53% reduction from 2019 baseline

SDG Alignment
Targets: 12.2, 12.5, 13.2

Operateresponsibly

1 Practice strong corporate governance and compliance
2 Act ethically and with integrity
3 Uphold high standards for data security and privacy
4 Foster a responsible supply chain

Through onsite generation, purchased renewable electricity, renewable energy
credits, and Green-e certified nature-based carbon credits.
†

100% strategic suppliers committed to reducing their environmental footprint
11% spend with diverse suppliers (US)Top industry rating for DJSI, Sustainalytics, Just Capital, and others

SDG Alignment
Targets: 9.2, 10.3, 17.16

5 Advance product quality and safety
Core sites: San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison,
UK Illumina Centre, the Netherlands, and Singapore Woodlands.

Ensure 100% strategic suppliers committed to reducing their environmental footprint
Achieve 20% spend with diverse suppliers (US)Achieve top industry CSR ratings

Leadership: manager, equivalent, and above.

*

Executive leadership: director, equivalent, and above.

‡

Underrepresented minorities (US): Black, Native, Pacific Islander, Hispanic or Latino, two or more.
Minorities (US): Asian, Black, Native, Pacific Islander, Hispanic or Latino, 2 or more.

§**

As our business evolves and matures, we consistently evaluate our CSR strategy, targets and theconnection to our business priorities. Changes in leadership and macroeconomic trends have led toprioritization of our 2023 targets listed here. A deeper review with a double materiality lens is planned
for future inclusion and evaluation.

Table of contents

CEO message

Introduction

CSR at Illumina

Access2023 CSR Report

Accelerate accessto genomics

PeopleSustainability

Responsibility
17

Table of contents

CEO message

Introduction

CSR at Illumina

Strategic approachand impact
We are committed to accelerating access togenomics to realize health equity for billions
of people around the world. Making genomics
available to all is critical in realizing its potential
to save and improve lives. That’s why we are
driving down the cost of sequencing, expanding
access to advanced technology, and increasing
the diversity of genomics data.
K E Y O B J ECT I V ES

1

Be the engine of genomic innovation

2

Drive down the cost of sequencing

3

Expand the reach of genomics

2023 H I G H L I G H TS

UN SDGS

211

352

335

1.3 billion

patients supported throughphilanthropic iHope programming

PeopleSustainability

Responsibility
182023 CSR Report

new patent applications in 2023,
totaling 9893 patents issued
worldwide by end of 2023

Accessunits of new breakthrough
NovaSeq X series shipped

lives covered> 27,000 health care professional learners reachedTable of contents

CEO message

Introduction

CSR at Illumina

Access2023 CSR Report

Nurture our people
and communities

PeopleSustainability

Responsibility
19

Table of contents

CEO message

Introduction

CSR at Illumina

Strategic approachand impact
We are committed to creating a workplace centered on
innovation and care that values the unique talents of theindividual, brings forward the best of the collective, anddelivers on the Illumina mission at a global scale.
We are also committed to giving back, creating shared value through our business,and seeking opportunities to engage our people to be agents of change.
Our extraordinary mission requires extraordinary people and leaders at every
level. By nurturing an inclusive and caring culture, we magnify the value ofcollaboration and building a community. Together our impact is amplified,and our potential is unlimited.
K E Y O B J ECT I V E S

1Practice diversity, equity, and inclusion

2

Attract extraordinary talent

3

Invest in our people

4

Support employee health, safety, and well-being

5

Engage our people and communities

2023 H I G H L I G H T S

female workforce
representation

52%

minority representationin the US workforce

PeopleSustainability

Responsibility
202023 CSR Report45%

Access5%

increase in female
executive leadership in
the last three years

58%

employee participation ingiving and volunteering

Zero net
pay gap
maintained for a fifth
consecutive year

350K

STEM learners
reached for 2023

UN SDGSTable of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
212023 CSR Report

Our people

Everyone at Illumina is driven by the powerof genomics to positively impact the world.
We seek opportunities. We embracechallenges. We work tirelessly to movegenomics and humanity forward.

5559 AMR

1365 EMEA

2384 APAC

54% 45%Male<1%

FemaleOther/undisclosed

E M P LOY E E AG E D I S T R I B U T I O N (G LO B A L)

17%

Under 30

9308

Total global employees (FTE)

67%

16%

30-50

Over 50

A D D I T I O N A L I D E N T I T I E S (U S)

3%
LGBTQ

2%

Veterans

10%

Persons with disabilities

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
222023 CSR Report

Integrate
sustainability

Scott
Sr. Specialist, Ethics & Privacy
Summit of Mt. Whitney, CATable of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
23

2023 CSR Report

Strategic approachand impact
We are committed to integrating environmental stewardshipinto the fabric of how we operate. Human health and the healthof our environment are intertwined, which is why we prioritize
taking action on climate change and implementing sustainable
solutions in our facilities, in our products, and across our value
chain. As the world seeks innovative solutions to tackle climate
challenges and protect our natural capital, we recognize theincredible opportunity genomics and our technology provide.
K E Y O B J ECT I V E S

1Drive climate action across our value chain

2

Operate sustainable facilities

3

Develop sustainable products

4

Leverage genomics for sustainability applications

2023 H I G H L I G H T S

100%

53%

Carbon neutral8%

renewable electricity*

direct operations (Scope 1, 2)
beyond†‡ SBTi path

reduction in packaging (since 2019)

decrease in water usage (YoY)

Through onsite generation, purchased renewable electricity, and renewable energy credits.

*

SBTi Beyond Value Chain Mitigation.

†

Through onsite generation, purchased renewable electricity, renewable energy credits, andGreen-e certified nature-based carbon credits.

‡

UN SDGS

NovaSeqTM X Series

NovaSeqTM 6000

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
242023 CSR Report

Our path to ascience-based
net-zero by 2050

Climate change represents a threat to human health, the environment, and theglobal economy. As a science-based organization, we aim to ground our climate
action in a science-based framework.
We were among the first companies in the world and the first genomic company
to receive verification of our 2050 net-zero emissions targets by the Science
Based Targets initiative (SBTi) Corporate Net-Zero Standard. Our Scope 1, 2, and3 emission targets are also externally verified by SBTi and aligned to the Paris
Agreement’s goal of keeping planetary warming to 1.5°C.

Managing climate risks and opportunities
To manage climate-related issues, we are incorporating climate resilience across ouroperations and value chain with a risk management structure, our EHS management
system, business continuity program management, supply chain risk reviews, andperiodic audits of related processes. As external conditions evolve, we will continue toevaluate our approach, recognizing that both physical risks, such as extreme weather,and transition risks, such as regulatory and technological developments, may affectour operations.
Learn more about how we manage climate risks and opportunities in our TCFD Index.

Illumina carbon footprint
Scope 1

Scope 2

Scope 3400

Scope 3 emissions

18.9

350

10

20.3
6.0

9.8

17.9

300

12.5

19.1

21.9

16.9

8

358.7
323.7
299.0

200

150

100%

12
11.4

250

SBTI-APPROVED TARGETS

Emission intensity*

5.8

238.1

6

242.4
4.2

•

Our most material Scope 3 categories
of focus include:

Short-term emission
reduction

•
•
•
•
•
•

Purchased goods and services (cat. 1)

4.1

4

Capital goods (cat. 2)
Upstream transportation and distribution (cat. 4)

100

Business travel (cat. 6)

250

Renewable electricity

Based on our Scope 3 emission baseline
assessment, more than 87% of our global
emissions are attributable to our Scope
3 emissions, making it imperative for us to
manage our value chain and work with our
suppliers on their decarbonization efforts.
We assessed all 15 Scope 3 categories andidentified the most material contributors.
Categories that represented 7% or more
were defined as material and accounted for
92% of our total Scope 3 footprint.

Increase annual sourcingof renewable electricity to
100% by 2030 from 2019baseline

0 GHG
Net zero

net-zero GHG emissions across•ReachIllumina's direct operations (Scope 1, 2)
and our value chain (Scope 3) by 2050
from 2019 baseline levels

↓90%

↓46%
absolute GHG•Reduceemissions from material

Scope 3 categories 46%
by 2030 from 2019baseline

Long-term emission reduction

Scope 1, 2 absolute GHG emissions•Reduce
90% by 2050 from 2019 baseline
absolute GHG emissions from
•Reducematerial Scope 3 categories 90% by 2050
from 2019 baseline

Employee commuting (cat. 7)
Investments (cat. 15)

2019

2020

2021

2022

2023

2030

2050

SBTi net-zero mitigation hierarchy

Net zero transition

Illumina follows the recommended mitigation hierarchy with our net-zero commitments. SBTi recommends science-based targets for the near and long term to address our value chain emissions and to implement
strategies to achieve these targets as a first order of priority, and then to invest in mitigation outside the value chains. Under the recommendations of the SBTi Corporate Net-Zero Standard, companies should go beyond
their near- and long-term science-based targets to further mitigate climate change by undertaking actions or making investments that generate additional co-benefits for people and nature. To further facilitate beyond
value chain mitigation, Illumina has invested in nature-based Green-e certified carbon offsets while on our journey to net zero. We have applied carbon offsets for our natural gas Scope 1 as a temporary mitigation.

As we work towards net zero, we're reducing emissions by
incorporating on-site energy generation and purchasing
renewable electricity, renewable energy credits, andGreen-e certified nature-based carbon credits.

Emissions in Kilotonnes.

Full emissions data here

*Scope 1 and 2 emission intensity per million dollars revenue.

Table of contents

CEO message

Introduction

2023 CSR Report

Operateresponsibly

CSR at Illumina

AccessPeopleSustainability

Responsibility
25

Table of contents

CEO message

Introduction

CSR at Illumina

Strategic approachand impact
We are committed to conducting ourselves with honesty,
integrity, and respect for all. Our role as a genomics pioneer
brings with it the responsibility to enable innovation for good,
ensuring that the technology we create and the data wecollect are used safely, ethically, and responsibly. Doing theright thing is core to who we are, what we do, and how we
do it. We honor the trust placed in us by patients, customers,
employees, shareholders, and communities.
K E Y O B J ECT I V E S

1Practice strong corporate governance and compliance2

Act ethically and with integrity

3

Uphold high standards for data security and privacy

4

Foster a responsible supply chain

5

Advance product quality and safety2023 H I G H L I G H T S

3$94.1 million

100%

97%

of Illumina core facilities* participatedin third-party audit programs

PeopleSustainability

Responsibility
262023 CSR Reportboard members are women

Accessin diverse supplier spend (US)employees trained on our code of conduct*Core sites: San Diego (i3, HQ, Distribution Center), Foster City, Hayward, Madison, UK Illumina Centre,
Netherlands, China, and Singapore Woodlands.

UN SDGSTable of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

Responsibility
272023 CSR Report

About this report?

Our report has been designed to provide a comprehensive and integrated viewof our commitments, progress, and activities related to our corporate social
responsibility program and most material environmental, social, and governance(ESG) themes.

Boundaries and exclusions

Assurance

The boundary of this report includes only core
Illumina activities.

Limited assurance has been provided in accordancewith ISAE 3000 and ISAE 3410 on the following topics:

Reporting period
January 1, 2023, to December 31, 2023, unlessotherwise indicated.

Baseline year
2019, unless otherwise indicated.

Materiality
Based on the materiality assessment refreshedin 2021.

Currency references
US dollars

Re-statements
We conduct ongoing data review to ensure accuracy
and consistency. Any material data changes would
be identified. In 2023, there was one restatement ofwater data noted as a footnote on page 77.

•Scope 1, 2, and 3 GHG •Water data
emissions data
•Waste data
Energydata••Human capital data
Reporting frameworks•In accordance with the GRI standards•Sustainability Accounting Standards Board (SASB)•Task Force on Climate-related Financial
Disclosures (TCFD)•UN Sustainable Development Goals (SDGs)•UN Universal Declaration of Human Rights•Dow Jones Sustainability Index•CDP•Bloomberg Gender Equality Index•HRC Corporate Equality Index•ISO 26000 as reference to provide guidance for*

integration of social responsibility

To access Illumina’s public facing CDP submission Learn more.

*

UNGC Communication on Progress Illumina participant page.

†C O N TACT

We welcome your feedback at csr@illumina.com
LEARN MORE

Illumina ESG reporting hub

Signatory participation•United Nations Global Compact (UNGC)•We Mean Business Coalition 1.5ºC•UN Race to Zero•CEO Action for Diversity & Inclusion•UN Women Empowerment Principles•STEMM Opportunity Alliance†

Relevant memberships•Business for Social Responsibility (BSR)•World Economic Forum•Association of Corporate CitizenshipProfessionals (ACCP)•Chief Executives for Corporate Purpose (CECP)•CSR Board.Org•World 50•Sustainable Packaging Coalition•My Green Lab

Table of contents

CEO message

Introduction

CSR at Illumina

AccessPeopleSustainability

2023 CSR Report

Disclosures
This report may contain forward-looking statements that involve risks and uncertainties.
Among the important factors to which our business is subject that could cause actual
results to differ materially from those in any forward-looking statements are: (i) changes
in the rate of growth in the markets we serve; (ii) the volume, timing and mix of customer
orders among our products and services; (iii) our ability to adjust our operating expenses toalign with our revenue expectations; (iv) our ability to manufacture robust instrumentationand consumables; (v) the success of products and services competitive with our own; (vi)challenges inherent in developing, manufacturing, and launching new products and services,
including expanding or modifying manufacturing operations and reliance on third-party
suppliers for critical components; (vii) the impact of recently launched or pre-announced
products and services on existing products and services; (viii) our ability to modify ourbusiness strategies to accomplish our desired operational goals; (ix) our ability to realize theanticipated benefits from prior or future actions to streamline and improve our R&D processes,
reduce our operating expenses and maximize our revenue growth; (x) our ability to further
develop and commercialize our instruments, consumables, and products; (xi) to deploy
new products, services, and applications, and to expand the markets for our technology
platforms; (xii) the risks and costs associated with our ongoing inability to integrate GRAIL
due to the transitional measures imposed on us by the European Commission as a result of
their prohibition of our acquisition of GRAIL and orders issued by the European Commission
and the Federal Trade Commission requiring that we divest GRAIL; (xiii) the risks and costs
associated with the expected divestment of GRAIL, including the possibility that the terms on
which we divest all or a portion of the assets or equity interests of GRAIL are materially worse
than those on which we acquired GRAIL; (xiv) our ability to satisfy the necessary conditions
to consummate the divestiture of GRAIL on a timely basis or at all, due to the requirements
set by the European Commission; (xv) the risk that disruptions from the consummation of
our acquisition of GRAIL and associated legal or regulatory proceedings, including appeals,
or obligations will harm our business, including current plans and operations; (xvi) the risk of
incurring additional fines associated with the consummation of our acquisition of GRAIL; (xvii)
our ability to obtain approval by third-party payors to reimburse patients for our products;(xviii) our ability to obtain regulatory clearance for our products from government agencies;(xix) our ability to successfully partner with other companies and organizations to develop
new products, expand markets, and grow our business; (xx) uncertainty, or adverse economic
and business conditions, including as a result of slowing or uncertain economic growth orarmed conflict; (xxi) the application of generally accepted accounting principles, which arehighly complex and involve many subjective assumptions, estimates, and judgments and (xxii)
legislative, regulatory and economic developments, together with other factors detailed in
our filings with the Securities and Exchange Commission, including our most recent filings on
Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and timeof which are released beforehand. We undertake no obligation, and do not intend, to updatethese forward-looking statements, to review or confirm analysts’ expectations, or to provide
interim reports or updates.

Stay up to date on recent news, stories, and more byconnecting with us.

Sam, director of public relations, sharing
the power of genomics to the next
generation of changemakers in China.

+1.800.809.4566 toll-free (US) +1.858.202.4566 tel
www.illumina.com©2024 Illumina, Inc.
All rights reserved. All other names, logos, and other trademarks are theproperty of their respective owners.

28